SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-22-023281
Filing Date
2022-09-30
Accepted
2022-09-30 08:45:22
Documents
15
Period of Report
2022-09-26
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20220929_8k.htm   iXBRL 8-K 40023
2 EXHIBIT 3.1 ex_427722.htm EX-3.1 94445
3 EXHIBIT 99.1 ex_428078.htm EX-99.1 15836
  Complete submission text file 0001437749-22-023281.txt   335839

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA navb-20220926.xsd EX-101.SCH 4036
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20220926_def.xml EX-101.DEF 14278
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20220926_lab.xml EX-101.LAB 18755
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20220926_pre.xml EX-101.PRE 14355
9 EXTRACTED XBRL INSTANCE DOCUMENT navb20220929_8k_htm.xml XML 4461
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 221282420
SIC: 2835 In Vitro & In Vivo Diagnostic Substances